66 related articles for article (PubMed ID: 18854288)
41. Ifosfamide in plasma cell leukemia: a report of two cases and review of the literature.
Malhotra H; Dhabhar BN; Saikia TK; Gopal R; Nadkarni KS; Nair CN; Advani SH
Am J Hematol; 1992 Jul; 40(3):226-8. PubMed ID: 1609777
[TBL] [Abstract][Full Text] [Related]
42. Interassay Comparison of the Tumor Markers CA125, CA15.3, and CA27.29.
Winston-McPherson GN; Merrill AE; Lo SY; Hoofnagle AN; Greene DN
J Appl Lab Med; 2017 Jul; 2(1):17-24. PubMed ID: 33636961
[TBL] [Abstract][Full Text] [Related]
43. [Case of plasmacytic variant of acute leukemia in a 13-year-old boy].
Nazarli AG; Kuliev SA; Peterburskaia RS
Pediatriia; 1975 Aug; (8):84-5. PubMed ID: 1196814
[No Abstract] [Full Text] [Related]
44. Rouleaux formation.
Abramson N
Blood; 2006 Jun; 107(11):4205. PubMed ID: 16739263
[No Abstract] [Full Text] [Related]
45. Poor clinical outcome of elderly patients with primary plasma cell leukemia treated with novel agents: real-world experience.
Saburi M; Sakata M; Takata H; Miyazaki Y; Kawano K; Sasaki H; Abe M; Kohno K; Soga Y; Nagamatsu K; Ono K; Nakayama T; Ohtsuka E
Leuk Lymphoma; 2022 Nov; 63(11):2691-2695. PubMed ID: 35687847
[No Abstract] [Full Text] [Related]
46. An atypical case of plasma cell leukemia.
Newman CL; Collichio FA; Bennett JM
Leuk Res; 1997 Oct; 21(10):1003-6. PubMed ID: 9403012
[No Abstract] [Full Text] [Related]
47. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.
Fernández de Larrea C; Kyle RA; Durie BG; Ludwig H; Usmani S; Vesole DH; Hajek R; San Miguel JF; Sezer O; Sonneveld P; Kumar SK; Mahindra A; Comenzo R; Palumbo A; Mazumber A; Anderson KC; Richardson PG; Badros AZ; Caers J; Cavo M; LeLeu X; Dimopoulos MA; Chim CS; Schots R; Noeul A; Fantl D; Mellqvist UH; Landgren O; Chanan-Khan A; Moreau P; Fonseca R; Merlini G; Lahuerta JJ; Bladé J; Orlowski RZ; Shah JJ;
Leukemia; 2013 Apr; 27(4):780-91. PubMed ID: 23288300
[TBL] [Abstract][Full Text] [Related]
48. Primary Plasma Cell Leukemia Associated with t(6;14)(p21;q32) and IGH Rearrangement: A Case Study and Review of the Literature.
Cho SY; Lim G; Oh SH; Lee HJ; Suh JT; Lee J; Lee WI; Lee HG; Yoon HJ; Park TS
Ann Clin Lab Sci; 2011; 41(3):277-81. PubMed ID: 22075513
[TBL] [Abstract][Full Text] [Related]
49. Plasma cell leukemia and hyperviscosity syndrome.
Geraci JM; Hansen RM; Kueck BD
South Med J; 1990 Jul; 83(7):800-5. PubMed ID: 2196691
[TBL] [Abstract][Full Text] [Related]
50. Microchip fluorescence-enhanced immunoaasay for simultaneous quantification of multiple tumor markers.
Shi M; Zhao S; Huang Y; Liu YM; Ye F
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Sep; 879(26):2840-4. PubMed ID: 21873123
[TBL] [Abstract][Full Text] [Related]
51. Serum tumour markers in patients with chronic kidney disease.
Xiaofang Y; Yue Z; Xialian X; Zhibin Y
Scand J Clin Lab Invest; 2007; 67(6):661-7. PubMed ID: 17852811
[TBL] [Abstract][Full Text] [Related]
52. Clinical value of CYFRA21-1, NSE, CA15-3, CA19-9 and CA125 assay in the elderly patients with pleural effusions.
Li CS; Cheng BC; Ge W; Gao JF
Int J Clin Pract; 2007 Mar; 61(3):444-8. PubMed ID: 17313612
[TBL] [Abstract][Full Text] [Related]
53. Increased serum CA125 levels in plasma cell dyscrasias.
Iwasaki T; Hamano T; Aizawa K; Kobayashi K; Kakishita E
Acta Haematol; 1997; 98(2):104-8. PubMed ID: 9286307
[TBL] [Abstract][Full Text] [Related]
54. Factors influencing serum concentration of CA125 and CA15-3 in Iranian healthy postmenopausal women.
Dehaghani AS; Ghiam AF; Hosseini M; Mansouri S; Ghaderi A
Pathol Oncol Res; 2007; 13(4):360-4. PubMed ID: 18158573
[TBL] [Abstract][Full Text] [Related]
55. Increased serum tumor markers (CA125 and CA15.3) in primary plasma cell leukemia: a case report and review of the literature.
de Larrea CF; Cibeira MT; Vallansot R; Colomo L; Bladé J
Clin Lymphoma Myeloma; 2008 Oct; 8(5):312-4. PubMed ID: 18854288
[TBL] [Abstract][Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
